Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
- Cremolini, C
- Antoniotti, C
- Lonardi, S
- Bergamo, F
- Cortesi, E
- Tomasello, G
- Moretto, R
- Ronzoni, M
- Racca, P
- Loupakis, F
- Zaniboni, A
- Tonini, G
- Buonadonna, A
- Marmorino, F
- Allegrini, G
- Granetto, C
- Masi, G
- Zagonel, V
- Sensi, E
- Fontanini, G
- Boni, L
- Falcone, A
Publication date
January 2018
DOI Publisher
Oxford University Press (OUP) ISSN
0923-7534 Language
EnglishAbstract
Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent. In this unplanned analysis of the TRIBE study, we investigated the prognostic and predictive impact of primary tumor sidedness in mCRC patients and the differential impact of the intensification of the chemotherapy in subgroups defined according to both primary tumor sidedness and RAS and BRAF mutational status
Add to ORKG